

Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



24 July 2026

National Stock Exchange of India Limited
Scrip Symbol: SUNPHARMA

BSE Limited
Scrip Code: 524715

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release

Enclosed herewith is a copy of the press release titled “Sun Pharma Notes Organon Shareholder Approval for Proposed Acquisition,” which shall be released after this intimation.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



FOR IMMEDIATE RELEASE

Sun Pharma Notes Organon Shareholder Approval for Proposed Acquisition

Mumbai, India and Princeton, NJ, July 24, 2026 - Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) ("Sun Pharma") today announced that the stockholders of Organon & Co. ("Organon") have approved the proposals in connection with the previously announced merger transaction under which Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., an indirect wholly owned subsidiary of Sun Pharma.

The shareholder approval marks an important milestone towards completion of the proposed transaction.

The acquisition remains subject to the satisfaction of the remaining customary closing conditions, including applicable regulatory approvals. For additional information regarding the proposed transaction, please refer to Sun Pharma's announcement dated [April 27, 2026](#).

About Sun Pharmaceutical Industries Limited. (CIN - L24230GJ1993PLC019050)

Sun Pharma is a leading global pharmaceutical company with a presence in Innovative Medicines, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun's high growth Global Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 22% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across five continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. "For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter)."

Contacts:

Investors

Dr. Abhishek Sharma

Tel +91 22 4324 4324, Xtn 2929

Tel (D) +91 22 4324 2929

Mobile +91 98196 86016

E mail abhi.sharma@sunpharma.com

Media

Gaurav Chugh

Tel +91 22 4324 4324, Xtn 5373

Tel (D) +91 22 4324 5373

Mobile +91 98104 71414

E mail gaurav.chugh@sunpharma.com